In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 million dollars. NASDAQ lists Menlo’s stock under the ticker symbol “MNLO.”
Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities served as the lead underwriters. Menlo’s stock price, MNLO, initially skyrocketed. However, the stock recently plummeted after poor test results costing investors millions of dollars.
Contact Our Firm if You’ve Invested in Menlo Therapeutics (“MNLO”)